Company Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-04-26 EDT			5-day change	1st Jan Change
2.59 ^USD	-11.12%		-33.61%	-47.68%

04-08	Genenta Science S.P.A. Announces Resignation of Board Members	CI
03-29	Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.

Number of employees: 14

Managers	Title	Age	Since
Bernhard Gentner FOU	Founder	-	14-07-23
Luigi Naldini FOU	Founder	-	14-07-23
Pierluigi Paracchi FOU	Founder	50	14-07-23
Richard B. Slansky DFI	Director of Finance/CFO	67	21-05-19
Carlo Russo CTO	Chief Tech/Sci/R&D Officer	71	20-12-31
Timothy J. Obara PRN	Corporate Officer/Principal	-	22-10-23

Members of the board	Title	Age	Since
Mark Sirgo CHM	Chairman	70	22-04-30
Anthony Marucci BRD	Director/Board Member	62	21-05-19
Roger Abravanel BRD	Director/Board Member	77	21-05-19
Pierluigi Paracchi FOU	Founder	50	14-07-23
Guido Guidi BRD	Director/Board Member	71	16-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,216,858	18,034,689 ( 99.00 %)	0	79.75 %
Stock B	1	18,216,958	11,023,081 ( 60.51 %)	0

Name	Equities	%	Valuation
Bank Julius Bär & Co. AG 2.265 %	412,547	2.265 %	1 M $
Kairos Partners SGR SpA 1.926 %	350,839	1.926 %	1 M $
Investitori SGR SpA 0.5116 %	93,200	0.5116 %	326 200 $
Anthilia Capital Partners SGR SpA 0.3206 %	58,400	0.3206 %	204 400 $
Algebris (UK) Ltd. 0.2063 %	37,576	0.2063 %	131 516 $
Lemanik Invest SA 0.0946 %	17,226	0.0946 %	60 291 $
BG Fund Management Luxembourg SA 0.0143 %	2,600	0.0143 %	9 100 $
UBS Securities LLC 0.0126 %	2,301	0.0126 %	8 054 $
Morgan Stanley Smith Barney LLC 0.002745 %	500	0.002745 %	1 750 $

Name	Equities	%	Valuation
Pierluigi Paracchi 12.60 %	2,294,421	12.60 %	8 M $
Raffaele Ospedale San 10.41 %	1,896,730	10.41 %	7 M $
Luigi Naldini 7.609 %	1,386,145	7.609 %	5 M $
Bernhard Gentner 3.803 %	692,871	3.803 %	2 M $
Carlo Russo 3.285 %	598,417	3.285 %	2 M $
Roger Abravanel 0.4346 %	79,165	0.4346 %	277 078 $
Richard B. Slansky 0.3949 %	71,940	0.3949 %	251 790 $
Guido Guidi 0.3543 %	64,539	0.3543 %	225 887 $
Stefania Mazzoleni 0.2285 %	41,620	0.2285 %	145 670 $
Mark Sirgo 0.1912 %	34,822	0.1912 %	121 877 $

Genenta Science SpA

Via Olgettina No. 58

20132, Milan

http://www.genenta.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.426 EUR

Average target price

21.37 EUR

Spread / Average Target

+780.73%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENENTA SCIENCE S.P.A.	-47.68%	47.18M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research